(1 - 10 from 14
)
BMS announces initial results for Opdivo plus Yervoy in liver ...
www.clinicaltrialsarena.com
Jun 4, — Bristol-Myers Squibb gastrointestinal cancers development lead Ian Waxman said: “Opdivo has been an important treatment option for patients ... › news › bms-opdiv...
News - Bristol-Myers Squibb, Ian Waxman - The Pharma Letter
www.thepharmaletter.com
Opdivo sBLA accepted for priority review in dMMR or MSI-H metastatic colorectal cancer The US Food and Drug Administration has accepted a ...
BMS scores FDA priority review for Opdivo/Yervoy combo in ...www.pmlive.com › pharma_news › bms_scores_fda_pr...
www.pmlive.com
... is the fastest rising cause of cancer-related death,” said Ian Waxman, development lead, gastrointestinal cancers, Bristol-Myers Squibb.
BMS’ trial of HCC drug fails to meet primary endpoint
www.clinicaltrialsarena.com
Bristol-Myers Squibb Gastrointestinal Cancers development lead Ian Waxman said: “We remain confident in the important role of Opdivo for the ...
sorted by relevance / date